Education
About Us
Working with TipRanks
Follow Us
Sonic Healthcare Limited (SKHHY)
OTHER OTC:SKHHY
Top Page
Sonic Healthcare
(OTC:SKHHY)
Select Model
Select Model
Rating:68Neutral
Price Target:
$16.50
▲(10.29% Upside)
Action:ReiteratedDate:02/19/26
The score is driven primarily by solid financial performance—especially strong free cash flow growth and stable margins—plus a constructive earnings outlook with reaffirmed EBITDA guidance. Offsetting these positives are weak technical signals (below key moving averages, negative MACD) and stated near-term operational risks in the U.S. and FX uncertainty, while valuation is supported by the dividend but tempered by a mid-range P/E.
Positive Factors
Free cash flow strength
Material FCF growth and strong earnings-to-cash conversion indicate durable cash generation. This supports dividends, maintenance capex, targeted acquisitions and debt reduction without relying on equity markets, giving management sustained financial flexibility across cycles.
Consistent organic growth and margin gains
Mid-single-digit organic growth across major markets with ~30bp margin expansion shows resilient demand and operational leverage. Sustainable margin improvement suggests scalable lab and imaging platforms and ongoing synergies from recent integrations.
Balance-sheet headroom and capital discipline
Maintaining investment-grade leverage targets with ~AUD1bn headroom and active property monetisation gives scope to fund strategic capex, selective M&A and shareholder returns while protecting credit metrics, supporting medium-term financial resilience.
Negative Factors
U.S. margin pressure and restructuring
Structural underperformance in the U.S., low organic growth and ongoing rationalisation create a persistent drag on group margins. Restructuring costs and slower recovery of volumes/collections can reduce consolidated profitability for multiple quarters.
Billing disruptions raised net debt and working capital
Disrupted U.S. billing/collections materially increased debtors and short-term liabilities, elevating net debt and working capital requirements. Until collections normalise, interest costs and liquidity flexibility remain constrained, delaying deleveraging plans.
Regulatory uncertainty in Germany
Pending private fee-schedule reform in Germany creates persistent reimbursement risk in a key growth market. Uncertain timing and magnitude of changes hinder pricing, margin forecasting and investment planning, potentially compressing future profitability.
Sonic Healthcare (SKHHY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.23B
Dividend Yield4.08%
Average Volume (3M)19.70K
Price to Earnings (P/E)10.8
Beta (1Y)0.49
Revenue Growth8.13%
EPS Growth-1.78%
CountryUS
Employees42,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.35
Shares Outstanding494,237,950
10 Day Avg. Volume29,893
30 Day Avg. Volume19,698
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.57
Price to Sales (P/S)1.35
P/FCF Ratio13.57
Enterprise Value/Market Cap2.44
Enterprise Value/Revenue2.26
Enterprise Value/Gross Profit7.95
Enterprise Value/Ebitda13.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.87
Revenue Forecast (FY)$7.75B
Sonic Healthcare Business Overview & Revenue Model
Company DescriptionSonic Healthcare Limited offers medical diagnostic services in Australia. The company provides laboratory medicine/pathology; diagnostic imaging/radiology, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry; and primary care medical services comprising general practice services, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, clinical trials, and chronic disease management programs to clinicians, hospitals, community health services, and their patients. It also offers administrative services and facilities to medical practitioners. The company operates in Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland, Belgium, and Ireland. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
How the Company Makes MoneySonic Healthcare generates revenue primarily through the provision of pathology and diagnostic imaging services. The company operates a network of laboratories and imaging centers that bill healthcare providers and patients for various tests and procedures. Key revenue streams include fees for blood tests, biopsies, radiological examinations, and other diagnostic services. Additionally, Sonic Healthcare engages in partnerships with healthcare systems and organizations, which can lead to long-term contracts and recurring revenue. The company also benefits from economies of scale, as its large operations allow for cost efficiencies and competitive pricing in the diagnostics market. Factors contributing to its earnings include the growing demand for diagnostic services, strategic acquisitions to expand its service offerings, and its established reputation for quality and reliability in the healthcare sector.
Sonic Healthcare Earnings Call Summary
Earnings Call Date:Feb 18, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 26, 2026
Earnings Call Sentiment Positive
Overall the call presents a largely positive operational and financial picture: strong H1 results (revenue, EBITDA, net profit), maintained full-year EBITDA guidance, margin improvement at group level (+30 bps), successful integration progress in major acquisitions (Germany LADR and Swiss deals), and continued organic growth across several markets (Australia, Germany, UK, Radiology). Offsetting these positives are concentrated challenges in the U.S. (margin pressure, restructuring and delayed revenue collection benefits), elevated short-term net debt and working capital due to acquisitions and the Change Healthcare billing disruption, FX headwinds for H2, and some regulatory/wage uncertainties (Germany GOA reform and Australian Fair Work outcomes). Management has clear remediation and capital management plans (operating review, sale-and-leaseback program, potential buybacks) and has retained guidance, supporting a constructive outlook despite identifiable near-term risks.Q2-2026 Updates
Positive Updates
Strong H1 Financial Results
Revenue of $5.445 billion, EBITDA of $907 million, net profit of $262 million and EPS of AUD 0.531 for H1 FY2026.
Organic Revenue Growth
Group organic revenue growth of 5% in H1 FY2026, reflecting broad-based underlying demand across key markets.
Adjusted EBITDA Margin Expansion
Adjusted EBITDA margins improved by c.30 basis points year-on-year (H1 2025 to H1 2026) after accounting for acquisition costs and other one-offs.
Germany: Strong Revenue Growth and Integration Progress
Germany achieved 40% revenue growth on a constant currency basis (organic growth ~5%). LADR acquisition settled 1 July and integration is progressing across 16 work streams with expected synergy capture and margin expansion.
United Kingdom Contract Wins and Growth
UK delivered organic growth of 24% driven by the Hertfordshire & West Essex (HWE) NHS contract; new hub lab in Watford to go live in July to service HWE.
Australia: Solid Pathology Performance
Australian Pathology achieved 5% organic growth; Medicare indexation of 2.4% applied to ~30% of schedule fees; successful private billing rollouts for selected tests and new services commenced at Hollywood Private Hospital (Perth).
Radiology and Clinical Services Momentum
Radiology organic revenue growth of 7% (EBITDA growth normalized +5%); Sonic Clinical Services revenue +5% and EBITDA +20% (off a low base) following integration of National Skin Cancer Clinics.
Advanced Diagnostics Expansion
Advanced diagnostics combining Cairo Diagnostics and ThyroSeq maturing into a nationwide offering; digital pathology rollout progressing with >60% dermatopathology volume on proprietary platform (PathologyWatch).
Capital Management and Dividend
Interim dividend increased 2.3% to AUD 0.45 (60% franked); capital priorities include maintaining investment-grade balance sheet, progressive dividends (medium-term payout target 70%-80%), selective acquisitions and potential share buybacks funded by property sales.
Balance Sheet Headroom and Guidance Maintained
Debt cover ratio at historic levels of 2.5x; available headroom of approximately $1.0 billion (pre-interim dividend); company reaffirmed constant-currency EBITDA guidance of $1.87–$1.95 billion and reduced depreciation guidance to $770–$780 million.
Active Property Monetisation Program
Sale and leaseback process launched for major Brisbane hub (Bowen Hills) targeting June 2026 completion with expected gain on sale; other sale-and-leaseback opportunities under consideration to fund potential buybacks.
Negative Updates
U.S. Operations Margin Pressure and Restructuring
Margin decline in U.S. operations due to low organic revenue growth and restructuring costs; operating review underway including rationalization of 9 anatomical pathology practices. U.S. underlying organic growth (after adjustments) ~2%.
Delayed Revenue Collection Benefits in U.S.
Enhanced revenue collection system expected benefits are slower and likely smaller than previously anticipated; previously flagged US revenue collection uplift (USD 20–25 million) now likely to fall into FY2027 rather than FY2026.
Working Capital and Net Debt Impact from Change Healthcare Breach
Change Healthcare cyber incident (Feb 2024) disrupted billing/collections in the U.S., inflating debtors and short-term liabilities; contributed to higher net debt and working capital which management expects to resolve by 30 June.
Acquisition-Related Margin Dilution and One-Off Costs
LADR acquisition had a lower initial margin than Sonic's average and was dilutive in H1; acquisition costs were $8 million in H1, and HWE contract margins remain improving but dilutive in the near term.
Foreign Exchange Headwind in Second Half
H1 FX produced a tailwind but management expects a materially smaller tailwind for the full year and a headwind in H2 versus H1 if current rates prevail; FX introduces uncertainty for EBITDA outcomes in H2.
Elevated Property-Related CapEx and Higher Reported CapEx
CapEx was higher in H1 primarily due to property transactions (Docklands acquisition settled ~1 July for ~AUD 100 million plus ~AUD 80 million fit-out). Near-term CapEx and working capital step-up increased reported net debt.
Wage Pressure and Regulatory Uncertainty in Australia
Phlebotomist pay changes quantified as sub-$2 million for this financial year, but Fair Work Commission health professionals' determination timing and impact remain uncertain and could create FY2027 wage pressure; industry discussions with government on offsetting funding ongoing.
Regulatory Uncertainty in Germany Private Fee Reform
Proposed GOA private fee schedule reform in Germany remains uncertain in timing and impact; management cannot yet quantify risk and is monitoring political/process developments.
Ongoing Restructuring Costs
Further U.S. restructuring costs to be incurred in H2 (management describes these as de minimis at group level but they will be a near-term headwind to margins).
Company Guidance
Sonic reaffirmed full‑year adjusted EBITDA guidance of AUD 1.87–1.95 billion (constant currency) after reporting H1 revenue of AUD 5.445 billion, EBITDA of AUD 907 million, net profit of AUD 262 million and EPS of AUD 0.531; management said group organic growth is running at c.5% and adjusted EBITDA margins were up ~30 basis points year‑on‑year (H1), with H1 acquisition costs of AUD 8 million. For the full year depreciation is now guided to AUD 770–780 million (constant currency), interest expense is expected to increase ~15% (constant currency) versus last year, and the effective tax rate is guided at 27%; the guidance assumes completed acquisitions only, current interest rates, and excludes any gains from property sales. Capital management priorities remain an investment‑grade balance sheet (debt cover ~2.5x), a progressive interim dividend of AUD 0.45 (up 2.3%, 60% franked; record 5 Mar, pay 19 Mar), available headroom ~AUD 1.0 billion pre‑dividend, potential sale‑and‑leaseback transactions (Brisbane hub targeted June 2026) with proceeds possibly funding on‑market buybacks, and near‑term capex for Docklands of c. AUD 20–30 million over the next six months (maintenance capex ~3–3.5% of revenue); FX provided a strong H1 tailwind and is still expected to be a net tailwind for the year but more modest if current rates prevail.Sonic Healthcare Financial Statement Overview
Summary
Income statement strength is supported by continued revenue growth (+6.52%) and stable gross margin (33.05%), while net margin pressure (5.32%) limits the score. Balance sheet metrics show moderate leverage (debt-to-equity 0.62) and softer ROE (6.17%), but a solid equity ratio (>50%) supports stability. Cash flow is a key positive with strong free cash flow growth (+72.66%) and solid earnings-to-cash conversion (FCF/NI 0.74).Income Statement
Sonic Healthcare has demonstrated a consistent revenue growth trend, with a 6.52% increase in the latest year, indicating strong market demand. However, the net profit margin has slightly decreased to 5.32%, suggesting some pressure on profitability. The gross profit margin remains stable at 33.05%, reflecting efficient cost management. EBIT and EBITDA margins are healthy, but there is room for improvement in operational efficiency.75
Positive
Balance Sheet
The company's debt-to-equity ratio has increased to 0.62, indicating a moderate level of leverage, which could pose a risk if not managed carefully. Return on equity has decreased to 6.17%, suggesting a decline in profitability relative to shareholder equity. The equity ratio remains strong at over 50%, indicating a solid capital structure.70
Positive
Cash Flow
Sonic Healthcare's cash flow performance is robust, with a significant 72.66% growth in free cash flow, highlighting strong cash generation capabilities. The operating cash flow to net income ratio is 0.58, indicating efficient conversion of earnings into cash. The free cash flow to net income ratio of 0.74 suggests effective cash management.80
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.80B | 9.65B | 8.93B | 7.96B | 9.31B | 8.75B |
| Gross Profit | 2.22B | 3.19B | 2.94B | 2.11B | 3.41B | 7.14B |
| EBITDA | 1.32B | 1.75B | 1.66B | 1.72B | 2.80B | 2.56B |
| Net Income | 396.13M | 513.60M | 511.09M | 684.98M | 1.46B | 1.32B |
Balance Sheet | ||||||
| Total Assets | 17.01B | 16.05B | 14.83B | 13.56B | 13.11B | 12.27B |
| Cash, Cash Equivalents and Short-Term Investments | 556.57M | 673.77M | 645.00M | 797.99M | 780.00M | 899.83M |
| Total Debt | 7.34B | 5.17B | 4.52B | 3.10B | 3.01B | 3.23B |
| Total Liabilities | 8.30B | 7.58B | 6.75B | 5.64B | 5.68B | 5.77B |
| Stockholders Equity | 8.55B | 8.32B | 7.92B | 7.74B | 7.27B | 6.38B |
Cash Flow | ||||||
| Free Cash Flow | 604.23M | 960.55M | 492.01M | 974.02M | 1.85B | 1.68B |
| Operating Cash Flow | 1.01B | 1.30B | 1.07B | 1.47B | 2.23B | 2.04B |
| Investing Cash Flow | -1.11B | -577.62M | -1.81B | -580.04M | -989.18M | -386.75M |
| Financing Cash Flow | 52.22M | -735.93M | 592.41M | -911.51M | -1.35B | -1.95B |
Sonic Healthcare Technical Analysis
Negative
14.96
Price Trends
15.47
Negative
14.90
Negative
15.37
Negative
Market Momentum
-0.17
Positive
36.91
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKHHY, the sentiment is Negative. The current price of 14.96 is below the 20-day moving average (MA) of 15.76, below the 50-day MA of 15.47, and below the 200-day MA of 15.37, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 36.91 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SKHHY.
Sonic Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $45.95B | 51.15 | 69.78% | ― | 8.39% | 21.44% | |
70 Neutral | $21.45B | 19.42 | 13.88% | 1.80% | 13.74% | 14.87% | |
68 Neutral | $7.23B | 10.84 | 6.39% | 4.08% | 8.13% | -1.78% | |
65 Neutral | $19.80B | -92.15 | -8.51% | ― | 14.47% | -353.69% | |
64 Neutral | $9.50B | 27.94 | 3.24% | 0.29% | 3.37% | -18.80% | |
62 Neutral | $4.81B | -287.63 | -1.88% | ― | 11.09% | -165.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SKHHY
Sonic Healthcare
14.71
-0.77
-4.99%
EXAS
Exact Sciences
103.75
58.05
127.02%
IDXX
Idexx Laboratories
577.12
154.97
36.71%
RVTY
Revvity
84.93
-24.68
-22.52%
DGX
Quest Diagnostics
195.23
30.28
18.36%
RDNT
Radnet
61.99
11.28
22.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.